Press release
Spinal Cord Injury Pipeline Analysis, Clinical Trials, 2025 by DelveInsight | EUSOL Biotech, Kringle Pharma, Mitsubishi Tanabe Pharma Corporation, Lineage Cell Therapeutics, NervGen Pharma, AlaMab The
Spinal Cord Injury Pipeline Analysis
DelveInsight reports that the Spinal Cord Injury pipeline features over 25 leading companies actively developing more than 30 therapies for the treatment of spinal cord injury.
DelveInsight's "Spinal Cord Injury - Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/spinal-cord-injury-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" offers a concise overview of the current pipeline landscape and future growth potential in spinal cord injury. The report covers disease background, treatment guidelines, and a comprehensive analysis of pipeline candidates, including their mechanisms, clinical progress, and development updates such as collaborations, funding, and designations.
Key Takeaways from the Spinal Cord Injury Pipeline Report:
*
DelveInsight's analysis of the spinal cord injury (SCI) pipeline reveals a dynamic landscape, with over 25 active companies developing more than 30 investigational therapies across various stages of clinical development.
*
In December 2024, the U.S. Food and Drug Administration (FDA) granted de novo classification and market approval to ONWARD Medical's ARC-EX system. This non-invasive spinal cord stimulation device is the first approved to enhance hand strength and sensation in individuals with chronic SCI, with clinical trials showing that 72% of participants experienced improved hand function and sensory perception.
*
In May 2024, the FDA approved Abbott's range of Spinal Cord Stimulation (SCS) systems-including Prodigy, Proclaim Plus, Proclaim XR, and Eterna-implantable neurostimulators designed to alleviate chronic pain in the torso, arms, and legs, providing relief for patients with otherwise intractable pain conditions.
*
Leading companies such as EUSOL Biotech Co., Ltd., Kringle Pharma, Mitsubishi Tanabe Pharma Corporation, Lineage Cell Therapeutics, NervGen Pharma, AlaMab Therapeutics, Axonis Therapeutics, NurExone Biologic, and others are actively developing novel drugs to advance SCI treatment options.
*
Notable pipeline candidates under investigation include ES-1601, MT-3921, NVG-291, among others, highlighting the promise of emerging therapies across different stages of development.
Spinal Cord Injury Overview
A spinal cord injury (SCI) refers to trauma-induced damage to the spinal cord or the nerve roots at the base of the spinal canal. This disruption interferes with the transmission of motor and sensory signals across the affected area. SCI is a disabling neurological condition with significant personal, psychological, and economic consequences, impacting both individuals and the healthcare system.
Spinal cord injuries are categorized as either complete or incomplete. A complete injury leads to a total loss of sensory and motor function below the site of the injury, whereas an incomplete injury allows for partial retention of function.
SCI can lead to either temporary or permanent loss of movement, sensation, or autonomic control below the site of damage. The extent of the impairment varies based on the location and severity of the injury. Common symptoms include paralysis (either quadriplegia or paraplegia), sensory deficits, bladder and bowel dysfunction, and issues with autonomic regulation such as unstable blood pressure. Injuries to the upper cervical spine can compromise respiratory function, making prompt medical care critical.
Overall, SCI profoundly affects a person's physical capabilities and quality of life, often requiring long-term medical, psychological, and social support.
Uncover the latest breakthroughs in SCI therapeutics, download our spinal cord injury market report [https://www.delveinsight.com/sample-request/spinal-cord-injury-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Spinal Cord Injury Pipeline Analysis
The Spinal Cord Injury pipeline insights report 2025 provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Spinal Cord Injury Market.
*
Categorizes Spinal Cord Injury therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Spinal Cord Injury drugs under development based on:
*
Stage of development
*
Spinal Cord Injury Route of Administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Spinal Cord Injury Mechanism of Action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Spinal Cord Injury Licensing Agreements
*
Funding and investment activities that support future advancements in the Spinal Cord Injury market.
Get Full Insights into the Spinal Cord Injury Pipeline and Future Market Trends - Download the Report Now: https://www.delveinsight.com/report-store/spinal-cord-injury-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Spinal Cord Injury Emerging Drugs
*
ES-1601: EUSOL Biotech Co., Ltd.
*
MT-3921: Mitsubishi Tanabe Pharma Corporation
*
NVG-291: NervGen
Spinal Cord Injury Pipeline Therapeutic Assessment
Spinal Cord Injury Assessment by Product Type
- Mono
- Combination
- Mono/Combination
Spinal Cord Injury By Stage
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Spinal Cord Injury Assessment by Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
Spinal Cord Injury Assessment by Molecule Type
- Monoclonal antibody
- Small molecule
- Peptide
Download the Spinal Cord Injury Sample Report for Key Insights on the Spinal Cord Injury Treatment Market and Therapeutics [https://www.delveinsight.com/sample-request/spinal-cord-injury-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Contents
1. Report Introduction
2. Executive Summary
3. Spinal Cord Injury Current Treatment Patterns
4. Spinal Cord Injury - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Spinal Cord Injury Late-Stage Products (Phase-III)
7. Spinal Cord Injury Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Spinal Cord Injury Discontinued Products
13. Spinal Cord Injury Product Profiles
14. Spinal Cord Injury Key Companies
15. Spinal Cord Injury Key Products
16. Dormant and Discontinued Products
17. Spinal Cord Injury Unmet Needs
18. Spinal Cord Injury Future Perspectives
19. Spinal Cord Injury Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Spinal Cord Injury Pipeline Reports Offerings [https://www.delveinsight.com/report-store/spinal-cord-injury-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=spinal-cord-injury-pipeline-analysis-clinical-trials-2025-by-delveinsight-eusol-biotech-kringle-pharma-mitsubishi-tanabe-pharma-corporation-lineage-cell-therapeutics-nervgen-pharma-alamab-the]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Spinal Cord Injury Pipeline Analysis, Clinical Trials, 2025 by DelveInsight | EUSOL Biotech, Kringle Pharma, Mitsubishi Tanabe Pharma Corporation, Lineage Cell Therapeutics, NervGen Pharma, AlaMab The here
News-ID: 4167140 • Views: …
More Releases from ABNewswire
Leading Law Group Targets Legal Equity for Women Facing Divorce and Custody Batt …
Women's Divorce & Family Law Group Helps Divorcing Individuals Overcome Uncertainty, Protect Their Assets, and Secure the Future of Their Families
CHICAGO, Illinois - As divorce rates in Illinois continue to reflect the growing complexities of modern family life, Women's Family Lawyers has announced an expansion of its dedicated legal services for individuals seeking professional guidance through the divorce process. Every Chicago Divorce Lawyer [https://www.womensfamilylawyers.com/family-law/chicago-divorce-lawyers/] on our team is committed to…
Inside Post-Realm FW26: A Cross-Cultural Vision at New York Fashion Week
The Post-Realm FW26 New York Fashion Show, presented by NotYetArt Inc., concluded on February 15, 2026, at 17 Saratoga Ave in New York as part of the CFDA listing.
Centered on the theme "Post-Realm," the showcase explored identity, structure, and transformation within contemporary fashion. The concept examined the space between tradition and futurism, East and West, and fashion and interdisciplinary art practices - positioning the runway as a platform for cross-cultural…
Sydney Business School Alumni Launch Australia's First AI-Driven Wholesale Inves …
Sydney Business School alumni Adnan Tanveer and Adam Newman are launching Investing Platform, Australia's first AI-driven wholesale investment marketplace, in Q1 2026. The platform addresses a key problem: qualified investors currently face seven months and thousands in fees to access a single alternative investment. The founders combine 20+ years of experience with hands-on AI development.
SYDNEY, AUSTRALIA - Investing Platform aims to cut months of friction from wholesale investor access.
Adnan Tanveer…
Sydney Fintech Founder Attending Emergence 2026 Ahead of Platform Launch
Sydney fintech founder Adnan Tanveer is attending Emergence 2026 investment conference (Feb 18-20) as he prepares to launch Investing Platform, Australia's first AI-driven wholesale investment marketplace. Tanveer and co-founder Adam Newman are building infrastructure to cut months of friction from how qualified investors access alternative investments. Platform launches Q1 2026.
SYDNEY, AUSTRALIA - Investing Platform preparing to launch Australia's first AI-driven wholesale investment marketplace.
Adnan Tanveer, co-founder of Investing Platform, is attending…
More Releases for Spinal
Evolving Market Trends In The Spinal Fusion Devices Industry: Advancements In Sp …
The Spinal Fusion Devices Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]._x000D_
_x000D_
What Is the Expected Spinal Fusion Devices Market Size During the Forecast Period?_x000D_
Over the past few years, there has been a significant growth in the spinal fusion devices market. The market is projected…
Key Influencer in the Spinal Fusion Devices Market 2025: Rising Spinal Disorder …
What Is the Forecasted Market Size and Growth Rate for the Spinal Fusion Devices Market?
The market for spinal fusion devices has experienced significant growth in the past couple of years. Expectations are that it will rise from estimates of $7.85 billion in 2024 to approximately $8.31 billion in 2025, giving us a compound annual growth rate (CAGR) of 5.8%. Factors contributing to this notable expansion during the historical period can…
Disposable Spinal Instrument Market: Revolutionizing Spinal Surgery with Hygiene …
Introduction
The medical device market has witnessed a surge in demand for disposable instruments, especially in areas where hygiene, precision, and efficiency are paramount. One such sector experiencing rapid growth is the disposable spinal instrument market. Spinal surgeries, being intricate and requiring high precision, have traditionally relied on reusable instruments. However, growing concerns about hygiene, infection control, and surgical efficiency have accelerated the shift toward disposable spinal instruments. These devices not…
Endoscopic Spinal Surgery Market: Minimally Invasive Solutions for Spinal Disord …
Global Endoscopic Spinal Surgery Market size was valued at US$ 667 Mn. in 2022 and the total revenue is expected to grow at a CAGR of 7.9% through 2022 to 2029, reaching nearly US$ 1137 Mn.
Endoscopic Spinal Surgery Market Overview:
Maximize Market Research is a research firm that has published a detailed analysis of the "Endoscopic Spinal Surgery Market". MMR in-depth market assessments in research reports consider significant technological advancements in…
Spinal Resilience: Acute Spinal Cord Injury Drug Pipeline Landscape (2023)
Market Outlook:
Charting Progress: Acute Spinal Cord Injury Drug Pipeline Landscape (2023)
The Acute Spinal Cord Injury Drug Pipeline Landscape sets its sights on a decade of advancements poised to redefine the trajectory of spinal resilience. This comprehensive outlook explores the unfolding strategies, innovations, and breakthroughs that promise to revolutionize the landscape of acute spinal cord injury treatment.
Market Drivers:
Neuroregeneration on the Horizon: At the forefront of the Acute Spinal Cord Injury Drug…
Spinal Laminoplasty Market - Revolutionizing spinal care with minimally invasive …
Newark, New Castle, USA: The "Spinal Laminoplasty Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Spinal Laminoplasty Market: https://www.growthplusreports.com/report/spinal-laminoplasty-market/8601
This latest report researches the industry structure, sales, revenue,…
